Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-65 years old~* Currently meet the DSM-IV-TR criteria for Major Depressive Disorder~* The patient's current depressive episode must be at least 8 weeks in duration~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control~* Patients with a history of meeting DSM-IV-TR criteria for:~  * any manic or hypomanic episode~ * schizophrenia or any other psychotic disorder~ * obsessive-compulsive disorder~* Patients who are considered a suicide risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.
- 2 (Type: EXPERIMENTAL): 80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing
- 3 (Type: EXPERIMENTAL): 120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing
- 4 (Type: PLACEBO_COMPARATOR): Matching placebo capsules, oral administration, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).